What is claimed is:

1. A method for treatment of Fabry disease in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective dose of migalastat or a salt thereof, wherein the patient has an α-galactosidase A mutation selected from the group consisting of: A29D, R38S, N53Y, Y88C, V124G, I133F, A143V, Y152N, F159C, A160D, D165N, F169I, L180V, D182G, R196T, W209R, A257T, P259S, G271A, S276T, M290V, A291S, I303T, I303V, L310V, G360A, G360R, G375A, L394P, G411S, and N419D.

2. The method of claim 1, wherein the migalastat or salt thereof is administered to the patient every other day.

3. The method of claim 1, wherein the patient is administered about 100 to about 150 mg free base equivalent of the migalastat or salt thereof every other day.

4. The method of claim 1, wherein the patient is administered about 123 mg free base equivalent of the migalastat or salt thereof every other day.

5. The method of claim 1, wherein the patient is administered about 123 mg of migalastat free base every other day.

6. The method of claim 1, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

7. The method of any one of claims 1-6, wherein the migalastat or salt thereof is administered orally.

8. The method of any one of claims 1-6, wherein the migalastat or salt thereof is administered by injection.

9. The method of any one of claims 1-8, wherein the migalastat or salt thereof enhances α-galactosidase A activity.

10. The method of any one of claims 1-9, wherein the patient is male.

11. The method of any one of claims 1-9, wherein the patient is female.

12. The method of any one of claims 1-11, wherein the mutation is A29D.

13. The method of any one of claims 1-11, wherein the mutation is R38S.

14. The method of any one of claims 1-11, wherein the mutation is N53Y.

15. The method of any one of claims 1-11, wherein the mutation is Y88C.

16. The method of any one of claims 1-11, wherein the mutation is V124G.

17. The method of any one of claims 1-11, wherein the mutation is I133F.

18. The method of any one of claims 1-11, wherein the mutation is A143V.

19. The method of any one of claims 1-11, wherein the mutation is Y152N.

20. The method of any one of claims 1-11, wherein the mutation is F159C.

21. The method of any one of claims 1-11, wherein the mutation is A160D.

22. The method of any one of claims 1-11, wherein the mutation is D165N.

23. The method of any one of claims 1-11, wherein the mutation is F169I.

24. The method of any one of claims 1-11, wherein the mutation is L180V.

25. The method of any one of claims 1-11, wherein the mutation is D182G.

26. The method of any one of claims 1-11, wherein the mutation is R196T.

27. The method of any one of claims 1-11, wherein the mutation is W209R.

28. The method of any one of claims 1-11, wherein the mutation is A257T.

29. The method of any one of claims 1-11, wherein the mutation is P259S.

30. The method of any one of claims 1-11, wherein the mutation is G271A.

31. The method of any one of claims 1-11, wherein the mutation is S276T.

32. The method of any one of claims 1-11, wherein the mutation is M290V.

33. The method of any one of claims 1-11, wherein the mutation is A291S.

34. The method of any one of claims 1-11, wherein the mutation is I303T.

35. The method of any one of claims 1-11, wherein the mutation is I303V.

36. The method of any one of claims 1-11, wherein the mutation is L310V.

37. The method of any one of claims 1-11, wherein the mutation is G360A.

38. The method of any one of claims 1-11, wherein the mutation is G360R.

39. The method of any one of claims 1-11, wherein the mutation is G375A.

40. The method of any one of claims 1-11, wherein the mutation is L394P.

41. The method of any one of claims 1-11, wherein the mutation is G411S.

42. The method of any one of claims 1-11, wherein the mutation is N419D.

43. The method of any one of claims 1-42, wherein the mutation is disclosed in a pharmacological reference table.

44. The method of claim 43, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease.

45. The method of claim 43, wherein the pharmacological reference table is provided in a product label for GALAFOLD®.

46. The method of claim 43, wherein the pharmacological reference table is provided at a website.

47. The method of claim 46, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.

48. A method of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease, the method comprising administering to the patient a therapeutically effective dose of migalastat or a salt thereof, wherein the patient has an α-galactosidase A mutation selected from the group consisting of:A29D, R38S, N53Y, Y88C, V124G, I133F, A143V, Y152N, F159C, A160D, D165N, F169I, L180V, D182G, R196T, W209R, A257T, P259S, G271A, S276T, M290V, A291S, I303T, I303V, L310V, G360A, G360R, G375A, L394P, G411S, and N419D.

49. The method of claim 48, wherein the migalastat or salt thereof is administered to the patient every other day.

50. The method of claim 48, wherein the patient is administered about 100 to about 150 mg free base equivalent of the migalastat or salt thereof every other day.

51. The method of claim 48, wherein the patient is administered about 123 mg free base equivalent of the migalastat or salt thereof every other day.

52. The method of claim 48, wherein the patient is administered about 123 mg of migalastat free base every other day.

53. The method of claim 48, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

54. The method of any one of claims 48-53, wherein the migalastat or salt thereof is administered orally.

55. The method of any one of claims 48-53, wherein the migalastat or salt thereof is administered by injection.

56. The method of any one of claims 48-55, wherein the patient is male.

57. The method of any one of claims 48-55, wherein the patient is female.

58. The method of any one of claims 48-57, wherein the mutation is A29D.

59. The method of any one of claims 48-57, wherein the mutation is R38S.

60. The method of any one of claims 48-57, wherein the mutation is N53Y.

61. The method of any one of claims 48-57, wherein the mutation is Y88C.

62. The method of any one of claims 48-57, wherein the mutation is V124G.

63. The method of any one of claims 48-57, wherein the mutation is I133F.

64. The method of any one of claims 48-57, wherein the mutation is A143V.

65. The method of any one of claims 48-57, wherein the mutation is Y152N.

66. The method of any one of claims 48-57, wherein the mutation is F159C.

67. The method of any one of claims 48-57, wherein the mutation is A160D.

68. The method of any one of claims 48-57, wherein the mutation is D165N.

69. The method of any one of claims 48-57, wherein the mutation is F169I.

70. The method of any one of claims 48-57, wherein the mutation is L180V.

71. The method of any one of claims 48-57, wherein the mutation is D182G.

72. The method of any one of claims 48-57, wherein the mutation is R196T.

73. The method of any one of claims 48-57, wherein the mutation is W209R.

74. The method of any one of claims 48-57, wherein the mutation is A257T.

75. The method of any one of claims 48-57, wherein the mutation is P259S.

76. The method of any one of claims 48-57, wherein the mutation is G271A.

77. The method of any one of claims 48-57, wherein the mutation is S276T.

78. The method of any one of claims 48-57, wherein the mutation is M290V.

79. The method of any one of claims 48-57, wherein the mutation is A291S.

80. The method of any one of claims 48-57, wherein the mutation is I303T.

81. The method of any one of claims 48-57, wherein the mutation is I303V.

82. The method of any one of claims 48-57, wherein the mutation is L310V.

83. The method of any one of claims 48-57, wherein the mutation is G360A.

84. The method of any one of claims 48-57, wherein the mutation is G360R.

85. The method of any one of claims 48-57, wherein the mutation is G375A.

86. The method of any one of claims 48-57, wherein the mutation is L394P.

87. The method of any one of claims 48-57, wherein the mutation is G411S.

88. The method of any one of claims 48-57, wherein the mutation is N419D.

89. The method of any one of claims 48-88, wherein the mutation is disclosed in a pharmacological reference table.

90. The method of claim 89, wherein the pharmacological reference table is provided in a product label for a migalastat product approved for the treatment of Fabry disease.

91. The method of claim 89, wherein the pharmacological reference table is provided in a product label for GALAFOLD®.

92. The method of claim 89, wherein the pharmacological reference table is provided at a website.

93. The method of claim 92, wherein the website is one or more of www.galafoldamenabilitytable.com or www.fabrygenevariantsearch.com.